home > news > detailed info


A major insight relating to the unreliability of data from continuous glucose monitors was published in the Nature journal, “Scientific Reports”, by Neil Theise, MD., the Lead Scientist of Pop Test, LLC and colleagues. The discovery of the “Interstitium”, a newfound human organ, by Dr. Theise and his collaborators, can be viewed by using the link

Continual glucose monitoring via an indwelling cutaneous needle measuring glucose in interstitial fluid (now identified to be in the “interstitium”) has been a game changer in the treatment of type 1 diabetes mellitus because of its accuracy. However, the needles used to collect this glucose containing fluid often fail in as little as a week. Despite the reliance on fluid from this space, the microanatomy of the interstitium has never been defined. The sensors currently in use were developed with the presumption of interstitial fluid being located somewhere in the sub-epidermal layers of the skin, but the actual anatomy relating to needle placement was always unclear.

Dr. Theise’s article elucidates a new understanding of the interstitial space as being supported by an interstitium organ, which has significant clinical management ramifications for diabetics undergoing continuous glucose monitoring. Elucidation by confocal laser of in-vivo endo-microscopy showed that the dermis is not dense connective tissue, as had previously been thought, but instead is a part of an interstitial space present in all tissues and organs and which is fluid filled and held open by a collagen bundle lattice. This finding suggests that needle placement of the monitors has not been optimized to lie fully within the interstitial place. Instead, the needle passes through the interstitial space into the sub-dermis. This deeper insertion may be prone to trigger a scar reaction or may dislodge the needle from the site causing the inaccuracy in data provided by the continuous glucose monitors.

Pop Test has developed a proprietary device platform to optimize placement of the sensor needle wholly within the dermal interstitium providing accurate data. Moreover, knowing the cellular and matrix components of the interstitium in ways previously unappreciated, allows for our development of proprietary materials that will not trigger interstitial fibrosis or other interfering reactions. These changes should lead to a more durable and optimized placement of glucose sensors. The Pop Test interstitial device will make continuous glucose monitoring the clinical success it should be. CGM makers such as Roche (OTCQX: RHHBY), Abbott (NYSE: ABT), Dexcom (NASDAQ: DXCM), and Medtronic (NYSE: MDT) might wish to take notice.

About Pop Test: Pop Test LLC is the company that developed a new saliva-based diabetes diagnostic platform that has been featured in presentations at the American Diabetes Association’s Annual Scientific Conference.

Pop Test has signed a Letter of Intent with QualHealth ( for commercialization of key technology.

QualHealth has provided a program through clinical dentistry which will significantly increase the number of diabetes screenings performed in the U.S. and around the world to help improve early detection of diabetes. QualHealth is planning a launch of the Pop Test Saliva Diabetes Screening tests in 2019.
Print this page
Send to a friend
News and Press Releases

ACG to Showcase its Range of Capsules and Engineering Solutions at Supply Side West, Las Vegas

ACG, the only supplier in the world offering end-to-end manufacturing solutions for the pharmaceutical and the nutraceutical industries, will be exhibiting its wide range of Engineering and Capsules solutions at this year’s Supply Side West, Las Vegas. At ACG’s booth, the visitors will be able to see the synergies created with coupling ACG’s Capsules and Engineering products, thereby leveraging the many benefits of integrated manufacturing.
More info >>

White Papers

Delivering Fit For Purpose Biomanufacturing CHO Cell Lines

Fujifilm Diosynth Biotechnologies

The challenge during mammalian cell line development is to identify and isolate stable, high expressing cell lines producing product with the appropriate critical product quality attributes rapidly, reproducibly and with relative ease. Obtaining a host cell line that inherently exhibits desirable biomanufacturing attributes can therefore have a significantly positive effect on the identification of recombinant cell lines with desired traits during cell line development screens. In this study, we demonstrate that it is possible to exploit intrinsic heterogeneity within host cell populations and identify host cell lines which are more “fit for purpose”.
More info >>

Industry Events

Pharma and Device Packaging and Labelling West Coast 2018

27-28 November 2018, Burlingame, CA

The second edition of the Pharma and Device Packaging and Labeling West Coast was a thought-provoking two days of engaging presentations, discussion and networking.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement